Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 12/20 | 0.45 |
| ▸ | ADA | P00813 | 1/20 | 0.40 |
| ▸ | PYGL | P06737 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL510325 | 1.00 | SLC5A2 (0.45) | SLC5A2ADAPYGLHIF1A | |
| SCHEMBL30025957 | 1.00 | SLC5A2 (0.45) | SLC5A2ADAPYGLHIF1A | |
| SCHEMBL7048838 | 0.73 | P2RY2 (0.60) | SLC5A2PYGL | |
| SCHEMBL6395173 | 0.73 | P2RY2 (0.60) | SLC5A2PYGL | |
| SCHEMBL937118 | 0.72 | KDM4E (0.54) | ADAPYGLHIF1A | |
| SCHEMBL509237 | 0.72 | KDM4E (0.54) | ADAPYGLHIF1A | |
| SCHEMBL5163143 | 0.72 | KDM4E (0.54) | ADAPYGLHIF1A | |
| SCHEMBL6884830 | 0.72 | KDM4E (0.54) | ADAPYGLHIF1A | |
| SCHEMBL6935273 | 0.72 | KDM4E (0.54) | ADAPYGLHIF1A | |
| SCHEMBL8791673 | 0.72 | KDM4E (0.54) | ADAPYGLHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017062797-A1 | THE METHODS FOR TREATMENT OF TUMORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-04-13 | — | — | WO | disclosed |
| EP-2014771-B1 | Continuous enzymatic hydrolysis process | ANADYS PHARMACEUTICALS INC (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20130137143-A1 | SEMI-CONTINUOUS AND CONTINUOUS ENZYMATIC HYDROLYSIS PROCESS | ANADYS PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20110091943-A1 | SEMI-CONTINUOUS AND CONTINUOUS ENZYMATIC HYDROLYSIS PROCESS | Andadys Pharmaceuticals, Inc. (US) | 2011-04-21 | — | — | US | disclosed |
| EP-2125738-A1 | IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHODS | 3M Innovative Properties Company (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1689361-A4 | THERAPEUTIC COMBINATIONS AND METHODS INCLUDING IRM COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1830876-A4 | TREATMENT FOR CUTANEOUS METASTASES | 3M INNOVATIVE PROPERTIES CO (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1804583-A4 | ADJUVANT FOR DNA VACCINES | 3M INNOVATIVE PROPERTIES CO (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-2014771-A1 | Semi-continuous and continuous enzymatic hydrolysis process | Anadys Pharmaceuticals, Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2009003042-A1 | SEMI-CONTINUOUS AND CONTINUOUS ENZYMATIC HYDROLYSISPROCESS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| EP-1613956-A2 | SELECTIVE ACTIVATION OF CELLULAR ACTIVITIES MEDIATED THROUGH A COMMON TOLL-LIKE RECEPTOR | 3M Innovative Properties Company (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2005067500-A2 | ENHANCEMENT OF IMMUNE RESPONSES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005065678-A1 | IMMUNOMODULATORY COMBINATIONS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005055932-A2 | THERAPEUTIC COMBINATIONS AND METHODS INCLUDING IRM COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005041891-A2 | NEUTROPHIL ACTIVATION BY IMMUNE RESPONSE MODIFIER COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005029037-A2 | SELECTIVE MODULATION OF TLR GENE EXPRESSION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005018574-A2 | IMMUNOSTIMULATORY COMBINATIONS AND TREATMENTS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005016273-A2 | INFECTION PROPHYLAXIS USING IMMUNE RESPONSE MODIFIER COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004091500-A2 | DELIVERY OF IMMUNE RESPONSE MODIFIER COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004087049-A2 | SELECTIVE ACTIVATION OF CELLULAR ACTIVITIES MEDIATED THROUGH A COMMON TOLL-LIKE RECEPTOR | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-10-14 | — | — | WO | disclosed |